Kirk Perry Takes Interim Leadership at Kenvue Amid Strategic Review

Kenvue Inc. (KVUE) has named Kirk Perry as its new Interim Chief Executive Officer, marking a significant leadership shift as the consumer health company pursues a comprehensive strategic evaluation. Perry, a veteran consumer packaged goods executive with more than three decades of industry experience, steps into the interim role immediately following the departure of former CEO Thibaut Mongon from the company and its Board of Directors.

The appointment comes as Kenvue’s Board, chaired by Larry Merlo, moves forward with efforts to drive shareholder returns and unlock growth potential. The Board has engaged Heidrick & Struggles, a leading executive search firm, to identify candidates for the permanent CEO position.

Kirk Perry’s Track Record and Executive Background

Perry brings substantial credentials to his interim role. Having joined Kenvue’s Board in late 2024, he most recently served as President and Chief Executive Officer of Circana, a prominent consumer intelligence company, where he continues to hold a board seat. His earlier career included serving as CEO of Information Resources, Inc., establishing a pattern of leadership across consumer-focused enterprises.

With his extensive background spanning global consumer goods, technology, and business transformation, Perry is positioned to guide Kenvue during a transitional period. The Board’s selection reflects confidence in his ability to execute the company’s strategic priorities while the search for permanent leadership continues.

Strategic Initiatives and Operational Focus

The Board has established a Strategic Review Committee to oversee the ongoing evaluation of strategic alternatives. According to Larry Merlo, the coordinated actions represent “ensuring we have the right talent, brand portfolio and operational foundation to fully capitalize on those strengths, accelerate profitable growth and best position the Company for future success.”

This restructuring addresses challenges facing the organization, including reported declines in organic sales performance. The company anticipates a net sales decline of 4 percent for the current quarter, with organic net sales expected to drop 4.2 percent.

Second Quarter Financial Expectations

Preliminary financial results reveal a company navigating market headwinds. Kenvue projects earnings per share in the range of $0.21 to $0.22 for the second quarter, with adjusted earnings per share between $0.28 and $0.29. Analyst consensus, however, runs higher, with 11 analysts on average forecasting earnings of $0.32 per share and revenue growth of approximately 3.38 percent to $4.03 billion for the quarter.

The divergence between company guidance and analyst expectations underscores the importance of Kirk Perry’s leadership and the Board’s strategic initiatives to restore momentum and reinforce market confidence in Kenvue’s ability to navigate competitive consumer health dynamics.